Non-commercial, grant-supported satellite symposia in conjunction with AMCP Nexus 2020 Virtual are developed by medical education organizations and offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit. There is no fee for pre-registering for the satellite sessions, registration is for planning purposes only. For additional information about a specific symposium, please contact the program manager listed.
Please email any satellite questions to satellitesymposia@amcp.org.
Monday, Oct. 19 | 9–10:30am
Provided jointly by Postgraduate Institute for Medicine and Impact Education, LLC.
Supported by an independent educational grant from UCB.
Continuing education credit available for pharmacists and physicians.
Program Description
Psoriatic disease is associated with several chronic comorbid conditions including heart disease, metabolic syndrome, diabetes, obesity, malignancies, gastrointestinal disorders, pulmonary disease, chronic kidney disease, and various infectious diseases. Quality of life (qoL) in patients with psoriasis alone is substantially lower than that in patients with other chronic conditions and the combined skin and joint involvement of PsA likely results in further reductions in QoL. The early average age of disease onset suggests patients with psoriatic disease patients will be impacted for a significant proportion of their life. This underscores its relevance to managed care organizations. Considering that patients with psoriasis alone require twice the health care resources over 12 months compared to the general population, it may be inferred that patients with the combination of skin and joint disease incur even greater costs due to the added burden of joint involvement. This symposium is designed to improve knowledge of psoriatic disease and its management among managed care and specialty pharmacy professionals.
Learn About
- Clinical trial data for existing and emerging psoriatic disease therapies
- Collaborative treatment decision-making, and treatment optimization via use of specialty pharmacy support services.
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
steve.casebeer@impactedu.net
Provided by Pharmacy Times Continuing Education.
Supported by an educational grant from Genentech, a member of the Roche Group.
Continuing education credit available for pharmacists.
Program Description
Approximately 9000 people in the United States are diagnosed with spinal muscular atrophy (SMA), and 1 in 50 people are carriers of the disease. Due to a high mortality rate associated with early-onset disease and different SMA type classifications, early intervention with genetic and newborn screening approaches is essential to predict severity and individualize patient treatment to control progression rates. Management of SMA has consisted primarily of supportive care to slow or prevent respiratory failure, nutritional compromise, and joint contractures. Patients with SMA who require supportive care for breathing difficulties, difficulty feeding and swallowing, and specialized occupational therapy incur exorbitant financial burden. Recently approved disease-modifying therapies have the potential to change the treatment landscape of SMA As new data on the safety and efficacy of emerging treatments for SMA emerge, it is imperative that managed care professionals make informed decisions for optimal care of patients with this disease.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Monday, Oct. 19 | 11am–12:30pm
Provided jointly by Postgraduate Institute for Medicine and Impact Education, LLC.
Supported by independent educational grants from bluebird bio and BioMarin.
Continuing education credit available for pharmacists and physicians.
Program Description
Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under investigation to ensure safety and efficacy. Furthermore, research in this field is particularly challenging given the inherent nature of rare diseases and genetic disorders. Approximately 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States.
Genetic disorders and other rare diseases present unique challenges for health insurers in terms of requisite clinical intervention, disease management, and economic burden. The treatment landscape in US health care has already evolved significantly over the past several decades and appears to be on the precipice of its most groundbreaking innovation to date gene therapy.
Learn About
- The solutions necessary to address the unique clinical and financial considerations surrounding gene therapies that will ensure quality care and appropriate patient access.
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
steve.casebeer@impactedu.net
Provided by PRIME Education, LLC.
Supported by independent educational grants from AstraZeneca, Daiichi-Sankyo, Inc., Puma Biotechnology, and Seattle Genetics.
Continuing education credit available for pharmacists, physicians, and nurses.
Program Description
The treatment paradigm for HER2+ MBC is rapidly transforming with the recent approvals of novel targeted therapies. These rapid changes have led to the evolution of guidelines, treatment sequencing strategies, and expansion of treatment options for patients with advanced disease. Join leading HER2+ MBC and managed care experts as they examine recent evidence and the impact on patient outcomes.
Using dynamic case and evidence-based discussions, the faculty will engage in an interactive presentation and discussion, where learners can develop their knowledge and competence in approaches to managed care decision-making and collaborative interprofessional problem solving.
Interactive panel discussions and real-time Q&A will offer you practical and evidence-based strategies for ensuring appropriate patient selection within the context of value-based care.
Top reasons to attend:
- The latest evidence and treatment guidelines
- A deep dive into novel targeted therapies for HER2+ MBC and their efficacy and safety
- Reviews of case-based scenarios to sharpen your skills in decision-making for complex patients, such as heavily pre-treated patients and patients with brain metastases
- Q&A with renowned experts in HER2+ MBC and managed care
Program Manager
Samantha Hoffman
PRIME Education, LLC
s.hoffman@primeinc.org
Monday, Oct. 19 | 5–6:30pm
Provided by PRIME Education, LLC.
Supported by an independent educational grant from Gilead Sciences, Inc.
Continuing education credit available for pharmacists, physicians, and nurses.
Program Description
Join rheumatology and managed care experts in this engaging program to learn how novel therapies are targeting inflammatory drivers that underpin rheumatoid arthritis (RA) and intersect with costly comorbidities and disability.
Using challenging cases, the faculty will illustrate how these therapies facilitate better clinical, patient, and economic outcomes despite previous treatment with conventional synthetic and biologic therapies. Interactive panel discussions and real-time Q&A will offer you practical and evidence-based strategies for ensuring appropriate patient selection within the context of value-based care.
Top reasons to attend:
- Hear expert analyses of the latest clinical trial data to inform managed care decisions
- Gain real-world insights into unmet patient needs and treatment considerations
- Learn strategies for balancing benefits and costs of RA treatment to achieve optimal outcomes
Program Manager
Samantha Hoffman
PRIME Education, LLC
s.hoffman@primeinc.org
Provided by Pharmacy Times Continuing Education.
Supported by an educational grant from Regeneron Pharmaceuticals.
Continuing education credit available for pharmacists.
Program Description
Neovascular age-related macular degeneration (AMD) is associated with central visual acuity loss that leads to severe visual impairment and blindness in an estimated 11 million Americans. Treatment with intravitreal anti-vascular endothelial growth factor (VEGF) agents have helped to preserve vision in many patients with neovascular AMD; however, improvements in vision preservation and quality of life come with a cost: regular, frequent office visits for monitoring, the burden of numerous intravitreal anti-VEGF injections, and financial strain for patients and caregivers. Real-world experience and outcomes with anti-VEGF agents have suggested that these barriers and burdens lead patients with AMD to receive fewer anti-VEGF injections and less frequent monitoring than guidelines recommend. Managed care professionals and pharmacists are seeing an increasing number of difficult-to-treat patients with AMD and must facilitate access to all anti-VEGF treatment options to individualize care for these patients. This activity will focus on the appropriate consideration of emerging therapies to treat neovascular AMD, factors that contribute to decreasing the disease burden, and use of best practices in cost management.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Monday, Oct. 19 | 7–8:30pm
Provided jointly by Medical Education Resources, Inc. and Impact Education, LLC.
Supported by an independent educational grant from Dexcom.
Continuing education credit available for pharmacists and physicians.
Program Description
Payers and employers alike place precedence on the clinical and economic burden of diabetes but are often unaware of the potential cost offsets garnered through effective, evidence-based therapy and emerging health technology interventions. In addition, the vast majority of plan members with diabetes have an A1C above ADA targets, putting them at risk for other costly comorbidities. Imprecise diabetes management culminating in hypoglycemic events can further result in excess health care resource utilization and reduced quality of life among members. To effectively address these clinical challenges and elicit improvements across 29 indices of glycemic variability and control, continuous glucose monitoring (CGM) has been endorsed by various professional endocrinology-centered organizations. This program will elucidate the clinical and economic burden of diabetes and describe multifaceted clinical and administrative strategies across the medical and pharmacy benefits to promote quality care and mitigate costs while improving outcomes for affected plan members.
Learn About
- How rtCGM and remote monitoring improves outcomes and reduces costs
- The latest benefits of using rtCGM over SMBG in Medicaid and Medicare plan beneficiaries
- The role of rtCGM as part of an employer-driven, population health management strategy
- The appropriate benefit design strategies to reduce health care system burden
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
steve.casebeer@impactedu.net
Provided jointly by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
Supported by an independent educational grant from AstraZeneca.
Continuing education credit available for pharmacists and physicians.
Program Description
For more than three decades, almost no treatment advances were made in small cell lung cancer (SCLC) until the checkpoint inhibitors finally propelled the SCLC treatment landscape forward with several recent regulatory approvals. More developments are expected in the near future on the SCLC treatment landscape.
This PeerView Live MasterClass and Practicum symposium will provide managed care professionals with a foundational overview of how cancer immunotherapies work and why/how this class of agents is different from other agents used in oncology, why they have revolutionized the management of cancer over the last few years, and how the management of SCLC is finally changing as a result of these therapies. In addition, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings will be presented, with specific implications for SCLC. Practical guidance will be provided for incorporating the latest clinical advances in immuno-oncology related to SCLC into benefit design, seamless drug distribution and dispensing, maximal patient safety, and effective communication with patients and care team clinicians.
Program Manager
Margaret Walker
PeerView Institute for Medical Education
Margaret.Walker@PeerView.com
Tuesday, Oct. 20 | 9–10:30am
Provided by Pharmacy Times Continuing Education.
Supported by educational grants from Acadia Pharmaceuticals and Acorda Therapeutics.
Continuing education credit available for pharmacists.
Program Description
In recent years, there have been numerous advances in therapies for Parkinson disease, but guidelines for treatment are far behind. The progressive impairment in motor functioning and worsening symptoms restricting autonomic, sensory, and neuropsychiatric functions cause significant burdens on patients’ quality of life. Although dopaminergic agents are effective for management of motor symptoms associated with Parkinson disease, they do not provide neuroprotective effects or alter progression of the disease. Such agents are also associated with frequent dose-limiting adverse effects that warrant the use of adjunctive medications and compound direct medical costs. This activity will review ongoing clinical trial data for agents targeting the α-synuclein pathology associated with Parkinson disease as well as new formulations with the potential to minimize motor-related complications. In the absence of long-term evidence for neuroprotection, managed care pharmacists should be able to address patient expectations regarding appropriate drug therapy, proper medication use and dosage, and current limitations of the medications available for Parkinson disease.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Provided by Creative Educational Concepts.
Supported by an independent educational grant from AstraZeneca.
Continuing education credit available for pharmacists and physicians.
Program Description
The last decade has seen expanded use of biomarker testing in non-small cell lung cancer (NSCLC) and a growing field of targeted therapies that have transformed the treatment landscape of advanced disease. The pace of changes in the field makes it difficult to translate the latest trial data and guideline recommendations into real-world practice. Gaps in appropriate testing or treatment can dramatically diminish survival gains seen in major cancer centers.
Managed care and specialty pharmacists will work through case scenarios involving the latest guideline recommendations for biomarker testing, currently available targeted therapies, and approaches to consider when balancing the cost and value of precision medicine. Use of audience response keypads and interactive case discussions will provide a lively forum for engagement for this important topic.
Program Manager
Ashley Lilly, MHA
Creative Educational Concepts
www.ceconcepts.com
Tuesday, Oct. 20 | 6:30–8pm
Provided by Creative Educational Concepts.
Supported by an independent educational grant from Merck & Co., Inc.
Continuing education credit available for pharmacists and physicians.
Program Description
Symposium attendees will gain insights into the molecular heterogeneity and diverse clinical features of TNBC, a condition which comprises 15-20% of all breast cancer cases, and has historically had limited treatment options, been associated with earlier age of onset, more aggressive disease course, and poorer prognosis. Attendees will also review the current state of immunotherapy research in TNBC, including completed and ongoing clinical trials across various stages of the disease continuum, the approval of emerging agents and indications throughout the treatment calculus, and prospective avenues of research focus, such as the identification of predictive novel biomarkers to help guide treatment decisions. Finally, using an interactive, case-based approach, this symposium will comprehensively evaluate current challenges in TNBC management and examine adaptive strategies that managed care and specialty pharmacists can employ to optimize patient outcomes in the era of immunotherapy.
Program Manager
Ashley Lilly, MHA
Creative Educational Concepts
www.ceconcepts.com
Provided by Pharmacy Times Continuing Education.
Supported by an independent educational grant from Eisai.
Continuing education credit available for pharmacists.
Program Description
In 2014, the classification of insomnia as a comorbid designation was revised, and it is now considered a disorder defined as difficulty with the initiation or maintenance of sleep. About 1 in 5 cases of insomnia becomes chronic and can persist for years, making the economic and quality of life burdens of insomnia significant, especially on vulnerable patient groups and those with coexisting medical or psychiatric disorders. Managed care professionals must converse with clinicians to improve knowledge and use of guideline recommendations and the role of cognitive behavioral therapy for insomnia (CBT-I) in clinical practice. Likewise, pharmacists involved in the treatment and management of patients with insomnia must accurately explain the risks and benefits of currently available insomnia drugs as well as emerging treatment approaches. The up-to-date information explored in this program will help managed care professionals incorporate cost-effective pharmaceutical care and protocols into practice to provide high-quality care to patients with insomnia.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Wednesday, Oct. 21 | 9–10:30am
Provided jointly by Medical Education Resources, Inc. and Impact Education, LLC
Supported by an independent educational grant from Merck & Co., Inc.
Continuing education credit available for pharmacists and physicians.
Program Description
The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000.
A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations.. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.
Learn About
- Guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making.
Program Manager
Steven Casebeer,MBA
Impact Education, LLC
steve.casebeer@impactedu.net
Provided by Pharmacy Times Continuing Education.
Supported by an independent educational grant from Biogen Inc.
Continuing education credit available for pharmacists.
Program Description
Alzheimer Disease (AD) is the sixth leading cause of death and the most common etiology for dementia. It causes a significant burden to the public health system; patients afflicted with it, and their caregivers. Continuing professional education will increase competency on Alzheimer’s disease including the importance of early detection, patient and caregiver education, and the role of new therapeutic targets for the treatment of AD. Application of knowledge will improve clinical decision making, improve quality of life among patients and caregivers, optimize medication therapy, improve outcomes, and decrease costs associated with the treatment of AD.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Wednesday, Oct. 21 | 6:30–8pm
Provided by Pharmacy Times Continuing Education.
Supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Continuing education credit available for pharmacists.
Program Description
Once a fatal condition, HIV is now considered a manageable and preventable chronic illness, though it requires a lifetime of medical care. Over time, the economic burden of HIV has shifted from direct costs of hospitalizations associated with advanced disease to costs associated with outpatient visits, lab tests, and antiretroviral therapy (ART) drugs. ART is the cornerstone of therapy for active, chronic HIV infection and treatment with these agents targets to decrease HIV RNA viral load to levels that are not detectable; however, choice of antiviral is complicated by their use as combination regimens and may further vary based on patient-specific factors and comorbidities. Managed care professionals have an important role in collaborating with clinicians to keep patients with HIV adherent to their prescribed ART regimen and engaged in their medical care. Pharmacists must recognize the potential advantages and emerging data for novel long-acting injectable and implantable ART formulations that may prevent treatment failure, combat nonadherence to therapy, and, ultimately, improve quality of life for patients with HIV.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Provided by Postgraduate Healthcare Education, LLC.
Supported by an independent educational grant from Pfizer Inc.
Continuing education credit available for pharmacists.
Program Description
This unique format is designed to deliver meaningful and actionable continuing education to pharmacists. The Translational Outcomes Forum consists of a live panel discussion including pharmacist therapeutic area experts and outcomes researchers. Through a candid sharing of insights, pharmacist learners will gain a real world understanding of methods that can be employed to analyze treatment outcomes data to be used for future treatment decision making. The Translational Outcomes Forum includes an interactive presentation with open discussion among the panelists and the audience of learners. The audience will be integrated into the discussion through the use of various interactive tools, Q&A, and the use of an audience response system (ARS). The panelists will be prepared to encourage participation and question asking through the creation of a "safe" environment where learners will feel comfortable participating. In this way, the thesis of the education will be delivered in a compelling manner that will facilitate learning, improve competence, and change practice ultimately leading to improved treatment outcomes. For AD, there is a need to use existing (or develop new) outcomes assessments that transcend measures of adherence for patients. Specifically, patient-reported outcomes (PROs) should be used to guide treatment selection, adjust current treatment, or switch therapies that are not working for a patient with AD. In many cases, clinicians treat patients with AD, and these patients improve; however, they never quite reach targets. Status quo becomes good enough, and clinical inertia becomes the norm.6 Clinical outcomes programs can help specialty and managed care pharmacists evaluate each patient with AD for their treatment's true value, identify best therapies, and improve care quality.
Program Manager
Robin Carrino
Postgraduate Healthcare Education, LLC
rcarrino@postgradhealthed.com
Thursday, Oct. 22 | 9–10:30am
Provided by Pharmacy Times Continuing Education.
Supported by an independent educational grant from Global Blood Therapeutics.
Continuing education credit available for pharmacists.
Program Description
Sickle cell disease (SCD) occurs by a mutation in the beta globin gene that affects normal production of hemoglobin in red blood cells. It is difficult for mutated, C-shaped hemoglobin blood cells to move within blood vessels and transport oxygen, causing damage to organs, infection, and other life-threatening complications that can result in hospitalizations and significantly reduced quality of life for patients. Previous treatment strategies have focused on managing and preventing acute symptoms, but new disease-modifying therapies have the potential to reduce hospitalizations and associated disease burden. However, with lifetime costs of care for an adult patient with SCD estimated at $1 million, these positive outcomes present additional challenges for managed care professionals as pediatric patients with SCD transition into adulthood. Pharmacists are essential members of the multidisciplinary care team and should be involved discussions with managed care professionals surrounding healthcare resource utilization and implementing strategies to manage lifelong complications in the care of patients with SCD. This activity will further explore their important roles in the management of patients with SCD from determining appropriate use of newly approved treatments to ensuring adherence and recommending dose adjustments that limit disease progression and associated complications to optimize cost-effective treatment for patients with SCD.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Provided jointly by Purdue University and PVI, PeerView Institute for Medical Education.
Supported by an educational grant from Greenwich Biosciences, Inc.
Continuing education credit available for pharmacists and physicians.
Program Description
Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. In 2018, a prescription pharmaceutical formulation of highly purified cannabidiol (CBD) was approved for the treatment of seizures in patients 2 years of age or older with DS and LGS, making it the first plant-derived cannabis-based medicine approved by the FDA, and in July 2020, the FDA expanded the label of this CBD formulation to include the treatment of seizures associated with TSC. In this interactive symposium, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy.
Program Manager
Margaret Walker
PeerView Institute for Medical Education
Margaret.Walker@PeerView.com
Thursday, Oct. 22 | 6:30–8pm
Provided by Pharmacy Times Continuing Education.
Supported by educational grants from bluebird bio, Inc. and Celgene Corporation.
Continuing education credit available for pharmacists.
Program Description
β thalassemia describes a hematologic genetic disorder that includes both deletions and mutations of genes involved in hemoglobin production. Hemoglobin, a protein in red blood cells, is responsible for binding to oxygen in the lungs and delivering it to tissues in the body. The hemoglobin protein comprises various chains, including α and β globin chains, which both play an integral role in the proper oxygenation of the body. Chromosome 11 contains genes involved in β production, and chromosome 16 contains genes related to α production. Severity of thalassemia is dependent upon the extent of genetic changes. Some patients may be asymptomatic carriers, and others may require lifelong blood transfusions to treat chronic anemia along with other comorbidities. If left untreated, transfusion-dependent thalassemia (TDT) may lead to life-threatening anemia. Red blood cell transfusions are the cornerstone of current therapy to maintain adequate hemoglobin levels. Lifelong transfusions are usually required every 2-5 weeks and include significant risks, such as blood-borne infection (primarily hepatitis B and C in developing countries) and iron overload. Acute reactions from transfusion may include hemolytic (intravascular) reactions, anaphylactic reactions, febrile non-hemolytic reactions, allergic (urticarial) reactions, and transfusion related acute lung injury. Delayed reactions may include alloimmune reactions, hemolytic (extravascular) reactions, and graft-versus-host disease. As new treatments enter the therapy landscape and fulfil unmet medical needs, there is a need for managed care professionals, pharmacists, and payers to be well-informed regarding β thalassemia complications, treatment, and management.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Provided jointly by Postgraduate Institute for Medicine and Impact Education, LLC.
Supported by an independent educational grant from Biogen.
Continuing education credit available for pharmacists.
Program Description
Multiple sclerosis (MS) is associated with a broad spectrum of comorbid conditions including cardiovascular disease and mental health issues that exert a significant influence on patient morbidity, mortality, and quality of life. Comorbidity is associated with a longer delay between MS symptom onset and diagnosis, more severe disability at diagnosis even after accounting for diagnostic delays, greater disability progression, increased health-care utilization, and higher mortality. More than a dozen disease-modifying therapies (DMTs) are now available for the treatment of MS with several additional novel therapies in late stage development. The abundance of choice can lead to therapeutic inertia or the absence of treatment initiation or intensification when therapeutic goals are unmet. This symposium highlights opportunities for managed care and specialty pharmacy professionals to enhance the management of patients with MS by implementing and/or recommending evidence-driven practices based on current clinical trial data.
Learn About
- How the rapidly evolving treatment landscape challenges the ability of clinicians and health systems to identify the optimal balance between safety, efficacy, and overall value when making MS treatment decisions
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
steve.casebeer@impactedu.net
Friday, Oct. 23 | 9–10:30am
Provided by Medscape
Supported by an independent educational grant from Lundbeck.
Continuing education credit available for pharmacists.
Program Description
This program will review the burden of frequent migraine to provide a basis for the importance of using the most effective therapies as early as possible. The remaining presentations will review our understanding of both established and emerging therapies for the prevention of migraine. The goal will be to provide an understanding of the clinical data for preventive migraine therapies and a perspective of how this information could be used in the managed care setting.
Program Manager
TeLae Ellis
Medscape
tellis@medscapelive.com
Provided jointly by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
Supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck & Co., Inc.
Continuing education credit available for pharmacists, physicians, nurses and MOC.
Program Description
PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the potential of PARP inhibitors in cancer care include application of recommended testing strategies to guide patient selection, individualized treatment planning, and management of treatment-related toxicities.
In this PeerView MasterClass and Practicum web broadcast, oncology and pharmacy expert specialists will review the latest evidence on the use of PARP inhibitors in the treatment of different tumors—including breast, ovarian, pancreatic, and prostate cancers—as well as oncology value assessment frameworks and strategies for assessing the benefits, risks, and costs to guide decision-making regarding this class of agents. Additionally, practical guidance will be provided for optimizing the outcomes for cancer patients who may benefit from PARP inhibitor therapy in managed care settings.
Program Manager
Margaret Walker
PVI, PeerView Institute for Medical Education
Margaret.Walker@PeerView.com